[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352162-105":59,"doc-detail-352162-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","malignancies-in-patients-with-inborn-errors-of-immunity-insights-from-20-years-of-clinical-experience-in-qatar","Malignancies in Patients with Inborn Errors of Immunity - Insights from 20-Years of Clinical Experience in Qatar","","Inborn errors of immunity (IEI) are linked to a higher malignancy risk, yet the cancer spectrum, onset timing, and outcomes across IEI subgroups remain insufficiently described. A retrospective cohort study of IEI patients identified between 2005 and 2025 at a tertiary center in Qatar analyzed malignancy features, timing relative to IEI diagnosis, and clinical outcomes using the 2024 IUIS classification. Among 175 patients followed for a median of 8 years, 13.1% developed malignancy, with high overall mortality (47.8%). DNA repair defects showed early lethal cancers, while antibody deficiencies showed later-onset malignancy and frequent delayed IEI recognition.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/malignancies-in-patients-with-inborn-errors-of-immunity-insights-from-20-years-of-clinical-experience-in-qatar/352162/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/malignancies-in-patients-with-inborn-errors-of-immunity-insights-from-20-years-of-clinical-experience-in-qatar/352162.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study on IEI-related malignancies?","Question",{"text":112,"@type":113},"To characterize the spectrum, timing relative to IEI diagnosis, and clinical outcomes of cancer across different IEI subgroups.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted and what data sources were used?",{"text":117,"@type":113},"It was a retrospective cohort study of IEI patients identified from 2005 to 2025 at a tertiary center in Qatar, using the 2024 IUIS classification and consolidated data from Cerner and three immunodeficiency registries.",{"name":119,"@type":110,"acceptedAnswer":120},"Which IEI subgroup showed the earliest and highest-mortality malignancies?",{"text":121,"@type":113},"DNA repair defects, particularly ataxia-telangiectasia, were associated with early-onset malignancy and the highest mortality (87.5%).",{"name":123,"@type":110,"acceptedAnswer":124},"What did the study suggest about cancer surveillance and IEI recognition?",{"text":125,"@type":113},"Findings support risk-adapted cancer surveillance and emphasize timely recognition of IEI, noting that malignancy can be a sentinel presentation leading to diagnosis.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},352162,1790233737,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Original Research PUBLISHED 26 August 2026  \nDOI 10.3389/fimmu.2026.1938725  \nOPEN ACCESS  \nEDITED BY  \nMaurizio Miano,  \nGiannina Gaslini Institute (IRCCS), Italy  \nREVIEWED BY  \nReetika Malik Yadav,  \nIndian Council of Medical Research, India Kimberly Davidow,  \nAlfred I. duPont Hospital for Children, United States  \n*CORRESPONDENCE  \nSally Mahgoub Khalil  \n [SKhalil3@hamad.qa](SKhalil3@hamad.qa)  \nRECEIVED 15 July 2026  \nREVISED 13 August 2026  \nACCEPTED 14 August 2026  \nPUBLISHED 26 August 2026  \nCITATION  \nKhalil SM, Adeli M, Mohamed S, Thalappil S, Taha SA, Gamil A, Charif H, Ben-Omran T, Ehlayel MSand Al-Nesf MA (2026) Malignancies in patients with inborn errors of immunity: insights from 20-years of clinical experience in Qatar.  \nFront. Immunol. 17:1938725 .  \ndoi: 10.3389/fimmu.2026.1938725  \nCOPYRIGHT  \n© 2026 Khalil, Adeli, Mohamed, Thalappil, Taha, Gamil, Charif, Ben-Omran, Ehlayeland Al-Nesf. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nMalignancies in patients withinborn errors of immunity:  \ninsights from 20-years of clinical experience in Qatar  \nSally Mahgoub Khalil 1*, Mehdi Adeli 2, Sara Mohamed 1, Sherin Thalappil 1, Salma A. Taha 1, Amna Gamil 3,4,5,  \nHonar Charif 3,5, Tawfeg Ben-Omran 4,6, Mohammed S. Ehlayel 2 and Maryam Ali Al-Nesf 1,4,5  \n1Corporate Allergy and Immunology Division, Department of Medicine, Hamad Medical Corporation, Doha, Qatar, 2 Department of Pediatrics, Pediatric Allergy, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar, 3 Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar, 4Weill Cornell Medical College, Doha, Qatar, 5Qatar University, College of Medicine, Doha, Qatar, 6 Department of Pediatric Medicine, Sidra Medicine, Doha, Qatar  \nIntroduction: Inborn errors of immunity (IEI) are associated with an increased risk of malignancy; however, the spectrum, timing, and outcomes of cancer across different IEI subgroups remain incompletely characterized.  \nMethodology: We conducted a retrospective cohort study of patients with IEI, identiﬁed between 2005 and 2025, at a tertiary center in Qatar. Patients with conﬁrmed IEI and documented malignancy were included. Malignancy characteristics, timing relative to IEI diagnosis, and clinical outcomes were analyzed across IEI subgroups, based on the 2024 IUIS classiﬁcation, using the Cerner electronic medical record and three immunodeﬁciency registries (the Qatar National Primary Immunodeﬁcie ncy Disease Registry, the Adult Immunology Service Registry, and the Pediatric Immunology Registry), with cases consolidated across these sources.  \nResult: Among 175 patients with IEI followed for a median of 8 years, 23 (13 . 1%) developed malignancy, hematological cancers predominated (87.0%), with lymphoma as the most common subtype (47 . 8%) . Overall mortality was high (47 . 8%), with many deaths occurring within two years of malignancy diagnosis. Marked heterogeneity was observed across IEI subgroups. DNA repair defects, particularly ataxia–telangiectasia, were associated with early-onset malignancy and the highest mortality (87 . 5%) . In contrast, antibody deﬁciencies were characterized by later-onset malignancy, lower mortality (16.7%), and a pattern in which malignancy frequently preceded IEI diagnosis, suggesting delayed recognition. Younger age at malignancy diagnosis and IEI subtype were signiﬁcantly associated with mortality.  \nConclusion: Malignancy represents a major cause of morbidity and mortality inpatients with IEI, affecting 13 . 1% of our cohort and carry","cbCaib6bjVLGYzn7","https://ap.wps.com/l/cbCaib6bjVLGYzn7","pdf",585182,"English","# Introduction\n# Methodology\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"What was the main objective of the study on IEI-related malignancies?\",\"answer\":\"To characterize the spectrum, timing relative to IEI diagnosis, and clinical outcomes of cancer across different IEI subgroups.\"},{\"question\":\"How was the study conducted and what data sources were used?\",\"answer\":\"It was a retrospective cohort study of IEI patients identified from 2005 to 2025 at a tertiary center in Qatar, using the 2024 IUIS classification and consolidated data from Cerner and three immunodeficiency registries.\"},{\"question\":\"Which IEI subgroup showed the earliest and highest-mortality malignancies?\",\"answer\":\"DNA repair defects, particularly ataxia-telangiectasia, were associated with early-onset malignancy and the highest mortality (87.5%).\"},{\"question\":\"What did the study suggest about cancer surveillance and IEI recognition?\",\"answer\":\"Findings support risk-adapted cancer surveillance and emphasize timely recognition of IEI, noting that malignancy can be a sentinel presentation leading to diagnosis.\"}]","Malignancies in Patients with Inborn Errors of Immunity - Insights from 20-Years of Clinical Experience in Qatar | PDF",1790098016,25,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbb20be09315ab2e8b09b6d9a4a28496.webp",983,1389,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08b2c1877c2c5452a0cdbbbe6b9de178.webp",982,1388,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b632436d1851f67dc26becdeb961fdf.webp",981,1386,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d800183265764a9bebceb41b276cc072.webp",980,1385]